APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness
- 1 July 2018
- journal article
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 151 (1) , 1-7
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin responseClinica Chimica Acta, 2013
- Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factorsGenome Research, 2012
- HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variantsNucleic Acids Research, 2011
- Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesityClinical and Experimental Medicine, 2009
- Is it time to discard the apo B:apo A-I ratio as a predictor of cardiovascular disease?Nature Clinical Practice Cardiovascular Medicine, 2007
- Stroke mortality and the apoB/apoA‐I ratio: results of the AMORIS prospective studyJournal of Internal Medicine, 2006
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004
- Mechanistic Insights and Clinical Relevance of the Interaction between Acute Coronary Syndromes and Lipid MetabolismSeminars in Vascular Medicine, 2004
- Variations in the Promoter Region of the Apolipoprotein A-1 Gene Influence Plasma Lipoprotein(a) Levels in Asian Indian Neonates from SingaporePediatric Research, 2001
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJACC, 2000